SCHEMBL4208152

SCHEMBL4208152

CCCC(NC(=O)c1ccc(-n2ccnc2)cc1)C(=O)N1CCC2C1C(=O)CN2S(=O)(=O)Cc1cccc[n+]1[O-]

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 5/20 0.39
KDM1A O60341 1/20 0.36
CCR1 P32246 2/20 0.34
ADRB1 P08588 1/20 0.34
CTSS P25774 4/20 0.34
CTSV O60911 3/20 0.34
CTSL P07711 3/20 0.34
CTSB P07858 3/20 0.34
TDP1 Q9NUW8 1/20 0.34
ROCK2 O75116 1/20 0.34
UBE2N P61088 1/20 0.33
PREP P48147 1/20 0.33
FAP Q12884 1/20 0.33
GFER P55789 1/20 0.33
KMT2A Q03164 1/20 0.33
DRD2 P14416 2/20 0.32
DRD3 P35462 2/20 0.32
MAPT P10636 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4039333 0.90 CTSK (0.40) CTSKKDM1ACCR1ADRB1CTSS
SCHEMBL4042897 0.87 CTSK (0.41) CTSKKDM1ACCR1ADRB1CTSS
SCHEMBL4043324 0.86 CTSK (0.40) CTSKKDM1AADRB1CTSSCTSV
SCHEMBL4040494 0.86 CTSK (0.39) CTSKKDM1ATDP1ROCK2UBE2N
SCHEMBL4045224 0.83 CTSK (0.42) CTSKKDM1ACTSSCTSVCTSL
SCHEMBL4042149 0.83 CTSK (0.49) CTSKKDM1ACCR1CTSSTDP1
SCHEMBL4044537 0.82 CTSK (0.41) CTSKKDM1AADRB1CTSSCTSV
SCHEMBL4039424 0.82 CTSK (0.41) CTSKKDM1ACCR1ADRB1CTSS
SCHEMBL4040654 0.81 CTSK (0.41) CTSKKDM1ACCR1ADRB1CTSS
SCHEMBL4043586 0.80 CTSK (0.49) CTSKCTSSCTSLCTSBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885KDM1A 3980/4885CCR1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.